TMCnet News
GeneFab Announces Two Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024– Two accepted abstracts highlight innovative methods for gene expression regulation – – GeneFab’s synthetic biology capabilities and Advanced Therapies offerings enable development of affordable therapies globally with an end-to-end manufacturing network – – Company booth at ASGCT is located at #1641 – ALAMEDA, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- GeneFab, LLC (“GeneFab”), an expert contract research, development and manufacturing organization (CRDMO) today announced two poster presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, which will be held May 7 to 11, 2024 in Baltimore, MD. GeneFab employs expert genetic design and manufacturing methods to meet Advanced Therapy companies' needs. With a 92,000 square foot cGMP manufacturing facility in Alameda, California that supports various customer projects, including allogeneic cell therapy, CAR-T and synthetic biology research services. GeneFab’s synthetic biology research center in South San Francisco offers R&D services for genetic design and drug screening and their manufacturing team in Singapore supports highly cost-effective nucleic acid therapy manufacturing. GeneFab’s presentations highlight two new technologies for control of payload production from cell therapies. One presentation focuses on a novel method for regulating gene expression using FDA approved small molecules (IMiDs) that pass the blood brain barrier. The other presentation showcases the development of highly potent promoters that activate gene expression specifically in marophages in the anti-inflammatory state to enable control of macrophage phenotype. With manufacturing capabilities and innovative synthetic biology approaches that leverage OMICS data, machine learning, synthetic promoter design, and protein engineering, the GeneFab team is an end-to-end R&D, clinical, and commercial manufacturing Advanced Therapy CRDMO partner that achieves precise control over gene expression for therapeutic benefit. Information about the poster sessions is as follows: Poster Presentations Iterative Engineering of Polarization-State Responsive Synthetic Promoters for Autonomous Control of Macrophage Polarization Logic Additionally, GeneFab’s scientists will be available at booth #1641 for individual and group discussions. About GeneFab GeneFab Contact: GeneFab Media Contact: 
|
